Suppr超能文献

从产 ESBL 和 AmpC 的肠杆菌科中筛选对头孢他啶/阿维巴坦具有耐药性或敏感性降低的突变体。

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.

机构信息

Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London, UK.

Norwich Medical School, University of East Anglia, Norwich, UK.

出版信息

J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345. doi: 10.1093/jac/dky363.

Abstract

INTRODUCTION

Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam. Disturbingly, mutations in KPC carbapenemases can confer ceftazidime/avibactam resistance, which is sometimes selected during therapy. We explored whether this risk extended to AmpC and ESBL enzymes.

METHODS

Mutants were selected by plating AmpC-derepressed strains, ESBL producers and ceftazidime-susceptible controls on agar containing ceftazidime + avibactam (1 or 4 mg/L). MICs were determined by CLSI agar dilution; WGS was by Illumina methodology.

RESULTS

Using 2× MIC of ceftazidime + 1 mg/L avibactam, mutants were selected from all strain types at frequencies of 10-7-10-9. Rates diminished to <10-9 with 4 mg/L avibactam or higher MIC multiples, except with AmpC-derepressed Enterobacteriaceae. Characterized mutants (n = 10; MICs 4-64 mg/L) of AmpC-derepressed strains had modifications in ampC, variously giving Arg168Pro/His, Gly176Arg/Asp, Asn366Tyr or small deletions around positions 309-314. Mutants of ESBL producers (n = 19; MICs 0.5-16 mg/L) mostly had changes affecting permeability, efflux or β-lactamase quantity; only one had an altered β-lactamase, with an Asp182Tyr substitution in CTX-M-15, raising the ceftazidime/avibactam MIC, but abrogating other cephalosporin resistance. Mutants of ceftazidime-susceptible strains were not sequenced, but phenotypes suggested altered drug accumulation or, for Enterobacter cloacae only, AmpC derepression. In further experiments, avibactam reduced, but did not abolish, selection of AmpC-derepressed Enterobacteriaceae by ceftazidime.

CONCLUSIONS

Most mutants of AmpC-derepressed Enterobacteriaceae had structural mutations in ampC; those of ESBL producers mostly had genetic modifications outside β-lactamase genes, commonly affecting uptake, efflux, or β-lactamase quantity. The clinical significance of these observations remains to be determined.

摘要

简介

越来越多的革兰氏阴性菌感染采用新的β-内酰胺酶抑制剂组合进行治疗,例如头孢他啶/阿维巴坦。令人不安的是,KPC 碳青霉烯酶的突变可导致头孢他啶/阿维巴坦耐药,而这种耐药性有时在治疗过程中被选择。我们探讨了这种风险是否扩展到 AmpC 和 ESBL 酶。

方法

通过在含有头孢他啶+阿维巴坦(1 或 4mg/L)的琼脂平板上对去阻遏 AmpC 菌株、ESBL 产生菌和头孢他啶敏感对照物进行划线培养,选择突变体。通过 CLSI 琼脂稀释法测定 MIC;通过 Illumina 方法进行 WGS。

结果

使用 2×MIC 的头孢他啶+1mg/L 阿维巴坦,除 AmpC 去阻遏肠杆菌科外,所有菌株类型的突变体选择频率均为 10-7-10-9。当使用 4mg/L 阿维巴坦或更高的 MIC 倍数时,频率降至<10-9,除非 MIC 为 4-64mg/L。特征化的突变体(n=10;MIC 为 4-64mg/L)去阻遏 AmpC 的菌株中,ampC 发生了修饰,分别为 Arg168Pro/His、Gly176Arg/Asp、Asn366Tyr 或 309-314 位附近的小缺失。ESBL 产生菌(n=19;MIC 为 0.5-16mg/L)的突变体大多发生了影响通透性、外排或β-内酰胺酶数量的变化;只有一个突变体改变了β-内酰胺酶,CTX-M-15 中的 Asp182Tyr 取代导致头孢他啶/阿维巴坦 MIC 升高,但消除了其他头孢菌素的耐药性。未对头孢他啶敏感菌株的突变体进行测序,但表型表明药物蓄积改变,或者仅大肠埃希菌的 AmpC 去阻遏。在进一步的实验中,阿维巴坦降低了但没有完全消除头孢他啶对去阻遏肠杆菌科的选择。

结论

大多数去阻遏 AmpC 的肠杆菌科突变体的 ampC 发生了结构突变;ESBL 产生菌的突变体大多发生了β-内酰胺酶基因以外的基因修饰,通常影响摄取、外排或β-内酰胺酶数量。这些观察结果的临床意义仍有待确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验